Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP). Visit our Microbicides section for information on the development of topical PrEP products.

PrEP: latest news

PrEP resources

  • How to get PrEP in the UK

    In England, PrEP is available to people taking part in the PrEP Impact trial.In Wales, Scotland and Northern Ireland, PrEP is available through NHS sexual health clinics.It...

    From: Factsheets

    Information level Level 2
  • Pre-exposure prophylaxis (PrEP)

    PrEP is highly effective in preventing the sexual transmission of HIV. For PrEP to work well, it’s important to take the pills regularly.While PrEP can...

    From: Factsheets

    Information level Level 2
  • Using anti-HIV drugs to prevent HIV

    The goal of HIV treatment is an undetectable viral load. An undetectable viral load means that your blood has a level of HIV below the level which...

    From: Booklets

    Information level Level 2
  • PrEP

    This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing...

    From: HIV prevention briefing papers

  • Pre-exposure prophylaxis

    Pre-exposure prophylaxis is an experimental HIV-prevention strategy that would use antiretrovirals (ARVs) to protect HIV-negative people from HIV infection....

    From: Preventing HIV

    Information level Level 4

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • PrEP Messaging: Using radio to reach communities with oral PrEP messages

    Joel Odondi must be doing something right. The former chaplain for a girls’ school has become a trusted expert on HIV prevention to radio listeners across Kenya – delivering messages that correct misinformation, counter myths, explain scientific concepts, and frame public health debates on PrEP and a host of other issues related to HIV. Keeping an ear out especially for what young women need to hear, Odondi uses a powerful combination of responsiveness, accuracy and credibility to get the job done.

    13 November 2018 | Prepwatch
  • Trying to prevent and diagnose HIV at the same time – a Catch-22?

    The doctors were puzzled by the fact that it wasn’t quite HIV. If it became HIV they could treat it. If it didn’t become HIV and went away they could discharge him. But this just being short of HIV all the time confused them.

    11 November 2018 | Daily Maverick
  • The NHS Refused To Give This Man The HIV Prevention Drug. He Got HIV.

    A man who asked his local sexual health clinic for PrEP, the HIV prevention drug, but who was denied it because the NHS has capped the supply, was diagnosed as HIV-positive just a few months later, BuzzFeed News can reveal.

    04 November 2018 | BuzzFeed
  • PrEP: The battle against stigma

    FS asked 756 gay and bisexual men for their thoughts on PrEP. The results show a rift between the opinions of those who are taking PrEP and those who oppose it.

    29 October 2018 | GMFA
  • Why black gay men need PrEP

    Black gay and bisexual men are far less likely than their white counterparts to take PrEP.

    29 October 2018 | GMFA
  • PrEP: NHS 'must urgently offer' HIV breakthrough nationwide as study shows infections cut 25% in a year

    'Unacceptable' that PrEP provision in England is capped when there are no limits in other UK nations, National Aids Trust chief says

    22 October 2018 | The Independent
  • CDC Encourages Health Care Providers to “Prescribe HIV Prevention”

    The federal initiative aims to help clinicians and their patients understand and access PrEP and PEP.

    22 October 2018 | Poz
  • Truvada and the truth: is HIV prevention propelling the STI epidemic?

    In the MSM community, a rapidly expanding STI epidemic is fueling questions about whether the steadily rising number of people who start Truvada for HIV prevention subsequently change their sexual behavior in ways that increase their risk of contracting chlamydia, gonorrhea, syphilis and, in rarer cases, hepatitis C.

    21 October 2018 | The Guardian
  • Groundbreaking Australian HIV trial should be replicated, researchers say

    High-income countries with people at high risk of HIV should replicate a groundbreaking trial in Australia, which has seen new infections fall by 25% in one year following the rapid rollout of free HIV medication, researchers say.

    19 October 2018 | The Guardian
  • No Prevention, No End: AVAC Report 2018

    In just about 24 months, the world will arrive at the deadline for the UNAIDS "Fast Track" goals for ending the epidemic. The primary fast-track goal for HIV prevention is reduction in new diagnoses from roughly 2,000,000 a year, to less than 500,000. There's no chance this goal will be achieved.

    18 October 2018 | AVAC
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.